Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RIPK1 | Q13546 | 4/20 | 0.71 |
| ▸ | CDK8 | P49336 | 9/20 | 0.70 |
| ▸ | AXL | P30530 | 2/20 | 0.70 |
| ▸ | PIK3CD | O00329 | 2/20 | 0.68 |
| ▸ | PIK3CA | P42336 | 2/20 | 0.68 |
| ▸ | PIK3CB | P42338 | 2/20 | 0.68 |
| ▸ | PIK3CG | P48736 | 2/20 | 0.68 |
| ▸ | FLT3 | P36888 | 3/20 | 0.57 |
| ▸ | PLK4 | O00444 | 2/20 | 0.57 |
| ▸ | ROCK2 | O75116 | 2/20 | 0.57 |
| ▸ | PRKD3 | O94806 | 2/20 | 0.57 |
| ▸ | MAP4K4 | O95819 | 2/20 | 0.57 |
| ▸ | INSR | P06213 | 2/20 | 0.57 |
| ▸ | CDK1 | P06493 | 2/20 | 0.57 |
| ▸ | ROS1 | P08922 | 2/20 | 0.57 |
| ▸ | FER | P16591 | 2/20 | 0.57 |
| ▸ | CDK2 | P24941 | 2/20 | 0.57 |
| ▸ | MARK3 | P27448 | 2/20 | 0.57 |
| ▸ | FLT4 | P35916 | 2/20 | 0.57 |
| ▸ | KDR | P35968 | 2/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16746926 | 1.00 | RIPK1 (0.71) | RIPK1CDK8AXLPIK3CDPIK3CA | |
| SCHEMBL4831501 | 0.87 | CDK8 (0.81) | RIPK1CDK8AXLPIK3CDPIK3CA | |
| SCHEMBL14365353 | 0.83 | RIPK1 (0.57) | RIPK1CDK8AXLPIK3CDPIK3CA | |
| SCHEMBL22978455 | 0.83 | RIPK1 (1.00) | RIPK1CDK8AXLPIK3CDPIK3CA | |
| SCHEMBL12127266 | 0.83 | RIPK1 (0.71) | RIPK1CDK8AXLPIK3CDPIK3CA | |
| SCHEMBL413503 | 0.83 | RIPK1 (0.71) | RIPK1CDK8AXLPIK3CDPIK3CA | |
| SCHEMBL15871324 | 0.83 | RIPK1 (0.71) | RIPK1CDK8AXLPIK3CDPIK3CA | |
| SCHEMBL410704 | 0.82 | CDK8 (1.00) | RIPK1CDK8AXLPIK3CDPIK3CA | |
| SCHEMBL13854143 | 0.82 | NUDT1 (0.56) | RIPK1CDK8AXLPIK3CDPIK3CA | |
| SCHEMBL416750 | 0.81 | PIK3CA (1.00) | RIPK1CDK8AXLPIK3CDPIK3CA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 123 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250179130-A1 | METHODS AND SYSTEMS FOR DESIGNING AND/OR CHARACTERIZING SOLUBLE LIPIDATED LIGAND AGENTS | ON TARGET THERAPEUTICS LLC | 2025-06-05 | — | — | US | disclosed |
| US-12060397-B2 | Soluble lipidated ligand agents for treating eye inflammation | TUFTS MEDICAL CENTER (US) | 2024-08-13 | — | — | US | disclosed |
| CN-112424201-B | Protein kinase inhibitors that promote liver regeneration or reduce or prevent hepatocyte death | 海帕瑞吉尼克斯股份有限公司 | 2024-04-02 | — | — | CN | disclosed |
| US-11912701-B2 | Protein kinase inhibitors for promoting liver regeneration or reducing or preventing hepatocyte death | HEPAREGENIX GMBH (DE) | 2024-02-27 | — | — | US | disclosed |
| US-11912701-B2 | Protein kinase inhibitors for promoting liver regeneration or reducing or preventing hepatocyte death | HEPAREGENIX GMBH (DE) | 2024-02-27 | — | — | US | disclosed |
| US-11912701-B2 | Protein kinase inhibitors for promoting liver regeneration or reducing or preventing hepatocyte death | HEPAREGENIX GMBH (DE) | 2024-02-27 | — | — | US | disclosed |
| US-20220281864-A1 | PROTEIN KINASE INHIBITORS FOR PROMOTING LIVER REGENERATION OR REDUCING OR PREVENTING HEPATOCYTE DEATH | HEPAREGENIX GMBH (DE) | 2022-09-08 | — | — | US | disclosed |
| EP-3571200-B1 | PROTEIN KINASE INHIBITORS FOR PROMOTING LIVER REGENERATION OR REDUCING OR PREVENTING HEPATOCYTE DEATH | HEPAREGENIX GMBH (DE) | 2022-06-22 | — | — | EP | disclosed |
| EP-3571200-B1 | PROTEIN KINASE INHIBITORS FOR PROMOTING LIVER REGENERATION OR REDUCING OR PREVENTING HEPATOCYTE DEATH | HEPAREGENIX GMBH (DE) | 2022-06-22 | — | — | EP | disclosed |
| CN-110291089-B | Protein kinase inhibitors for promoting liver regeneration or reducing or preventing liver cell death | 海帕瑞吉尼克斯股份有限公司 | 2022-05-27 | — | — | CN | disclosed |
| US-20080167338-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | PLEXXIKON INC | 2008-07-10 | — | — | US | disclosed |
| US-20080167338-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | PLEXXIKON INC | 2008-07-10 | — | — | US | disclosed |
| WO-2008079903-A1 | PYRROLO [2, 3-B] PYRIDINE DERIVATIVES AS KINASE MODULATORS | PLEXXIKON, INC. (US) | 2008-07-03 | — | — | WO | disclosed |
| WO-2008079903-A1 | PYRROLO [2, 3-B] PYRIDINE DERIVATIVES AS KINASE MODULATORS | PLEXXIKON, INC. (US) | 2008-07-03 | — | — | WO | disclosed |
| WO-2008080015-A2 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | PLEXXIKON, INC. (US) | 2008-07-03 | — | — | WO | disclosed |
| EP-1893612-A1 | PYRROLO [2, 3-B]PYRIDINE DERIVATIVES AS PROTEIN KINASE INHIBITORS | PLEXXIKON, INC. (US) | 2008-03-05 | — | — | EP | disclosed |
| WO-2007002325-A1 | PYRROLO[2,3-B] PYRIDINE DERIVATIVES AS PROTEIN KINASE INHIBITORS | PLEXXIKON, INC. (US) | 2007-01-04 | — | — | WO | disclosed |
| WO-2007002325-A1 | PYRROLO[2,3-B] PYRIDINE DERIVATIVES AS PROTEIN KINASE INHIBITORS | PLEXXIKON, INC. (US) | 2007-01-04 | — | — | WO | disclosed |
| WO-2007002433-A1 | PYRROLO [2, 3-B] PYRIDINE DERIVATIVES AS PROTEIN KINASE INHIBITORS | PLEXXIKON, INC. (US) | 2007-01-04 | — | — | WO | disclosed |
| WO-2007002433-A1 | PYRROLO [2, 3-B] PYRIDINE DERIVATIVES AS PROTEIN KINASE INHIBITORS | PLEXXIKON, INC. (US) | 2007-01-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080167338-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | MAP3K20, MAP3K13, MAP3K8 | RIPK1 507/4885CDK8 56/4885AXL 1354/4885 |
| US-11912701-B2 | Protein kinase inhibitors for promoting liver regeneration or reducing or preventing hepatocyte death | MAPK4, MAPK7, MAPK14 | RIPK1 71/4885CDK8 392/4885AXL 966/4885 |
| US-20220281864-A1 | PROTEIN KINASE INHIBITORS FOR PROMOTING LIVER REGENERATION OR REDUCING OR PREVENTING HEPATOCYTE DEATH | MAPK4, MAPK7, MAPK14 | RIPK1 76/4885CDK8 379/4885AXL 991/4885 |
| US-20250179130-A1 | METHODS AND SYSTEMS FOR DESIGNING AND/OR CHARACTERIZING SOLUBLE LIPIDATED LIGAND AGENTS | LDLR, HDLBP, LIPG | RIPK1 966/4885CDK8 2269/4885AXL 521/4885 |
| US-12060397-B2 | Soluble lipidated ligand agents for treating eye inflammation | LIPG, CD40, LDLR | RIPK1 395/4885CDK8 2153/4885AXL 627/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.